Qualität Charge für Charge
of cannabis-based medicine is evidence.
Cannabisbasierte Arzneimittel von Avextra
Avextra is extra
Because we take quality seriously, we control the full value chain of our products from growing to manufacturing and distribution
We have over 75 years of experience in botanical extraction and in manufacturing plant-based medicines.
We are fully committed to gathering and documenting evidence to support the therapeutic potential of cannabis-based medicines
Avextra collaborates with researchers and healthcare professionals to collect and aggregate real world patient data and RCTs to inform and support regulatory filings.
RESEaRCH & DEVELOPMENT
What differentiates Avextra from the rest?
- We invest one-third of our total budget in research and development
- We are focused on expanding the evidence base for therapy with cannabis-based medicines
- Ensure the efficacy and quality of our products
- Innovation is part of our DNA
Avextra‘s clinical trials and observational studies
Here you can find out more about Avextra's clinical program and the ongoing studies.
The Avextra Alliance for evidence-based Cannabis-Medicine
- Focused on collaborating with researchers, doctors and scientific associations
- To generate real world patient data in medical cannabis access programs
- With the aim of designing robust clinical trials for proprietary Cannabis-based medicines that can achieve regulatory approval
We are Specialists for Plant-Based Medicines
Patients in focus: Patients do not suffer from their illnesses alone but also from the symptoms and burdens of coping with serious illness. The goal of our research is to develop cannabis-based products that have proven effective in relieving symptoms.
Avextra's Cultivation in Portugal
Check out our state-of-the-art medical cannabis cultivation facility in Portugal in this behind-the-scenes tour!
VaLUE CHaIN
Complete control over the full value chain
Because cannabis has historically not been cultivated at scale for pharmaceutical production, developing cannabis-based medicines that comply fully with EU quality standards, requires an investment in the full production value chain
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
- standardised and consistent products
- fully compliant with regulatory specifications and quality standards for botanical drugs
- state-of-the-art pharmaceutical manufacturing facility Made in Germany
Our best guarantee for reliable and secure supply for our pharmaceutical production
The 10 000 m² production facility is located in the heart of Germany’s pharmaceutical manufacturing in the state of Hesse
The 10 000 m² production facility is located in the heart of Germany’s pharmaceutical manufacturing in the state of Hesse
The 10 000 m² production facility is located in the heart of Germany’s pharmaceutical manufacturing in the state of Hesse
The 10 000 m² production facility is located in the heart of Germany’s pharmaceutical manufacturing in the state of Hesse
EXPERT aREA
Service, Information and Documentation for Healthcare Professionals
Expert Area for Physicians
- Applications and Forms
- scientific publications
Expert Area for Pharmacists
- Availability of Products
- Identity Verification
- Application for prescription
Memberships
VCA - ASSOCIATION OF CANNABIS SUPPLYING PHARMACIES E.V.
The VCA is the professional association for pharmacies supplying cannabis in Germany. It is focused on developing competence, offers further education and promotes the exchange of content between pharmacists, industry, science and politics. The declared goal of the VCA is to ensure an efficient and affordable supply of medical cannabis to patients in Germany.
BPI - FEDERATION OF THE PHARMACEUTICAL INDUSTRY E.V.
The Federation of the Pharmaceutical Industry is the responsible industry association for research-oriented cannabis manufacturers. The BPI also represents the broad spectrum of the pharmaceutical industry on a national and international level. More than 270 companies have joined forces in the BPI.
The EUMCA acts as an authoritative voice of the medical cannabis industry, representing European manufacturers and suppliers of pharmaceutical-grade cannabis products. Its members are a diverse group of stakeholders.
Cooperation Partners
J.W. GOETHE UNIVERSITY FRANKFURT
Avextra Pharma is cooperating with J. W. Goethe University in a preclinical research project. In the future, the scientific findings of this work will help to tailor the composition of cannabis-based products even better to the respective medical indication. In this way, we would like to meet the individual needs of patients in an evidence-based manner.
CESPU
CESPU is a leading institute in Portugal in the field of pharmacy and toxicity. We collaborate on basic toxicology research.
IPS PHARMA
Together with IPS, we operate Integro Medical Cannabis Clinics in Great Britain. This clinic meets the highest quality standards and primarily treats patients with severe pain symptoms.
DGS
With around 4,000 members, the German Society for Pain Medicine is the largest society of practising pain therapists in Europe. Since its foundation in 1984, the medical society has been committed to improving the care of patients with chronic pain. Avextra is a supporting partner in the DGS "Cannabis Initiative 2022 /23" which seeks to improve patient access to Cannabis-based medicines.